On July 23rd, Nanjing-based 3D-printed drug company, Tridium Pharmaceutical Technology Co. ("BioNTech"), a next-generation immunotherapy company, to enter into a research collaboration and platform technology license agreement.
Under the agreement, the two companies will develop oral RNA drugs based on 3D printed drug technology to meet clinical needs by way of convenient oral formulations.
What is 3D printed drug technology? Simply put, it is the printing of APIs and excipients into special structures.In the partnership with BioNTech, Tridium will take advantage of 3D printed drug technology to innovatively design oral formulations to optimize RNA drug delivery and absorption.
RNA, known as ribonucleic acid, plays an important role in transmitting genetic information within the living body.
Triage is able to create unique external and internal structures for drug formulations, thereby optimizing the delivery of innovative RNA drugs. "Optimization" is manifested in the form of "printing" the drug to dramatically reduce degradation in the gastrointestinal tract and maximize delivery to potentially optimal sites of absorption in the gastrointestinal tract.
Under the terms of the agreement, San Diego will receive an initial payment of $10 million and is expected to receive product development, registration and commercialization milestone payments totaling more than $1.2 billion, as well as potential future tiered sales royalties.
About BioNTech SE
BioNTech (BioNTech) from Germany is a next generation immunotherapy research and development company founded in 2008, focusing on the development and production of immunotherapies for cancer, infectious diseases and other diseases.
The company is best known for collaborating with Pfizer to develop the first COVID-19 mRNA vaccine approved for emergency use, demonstrating leadership in mRNA technology, a vaccine that has broken several world records since its launch.
About Triassic
San Diego is a 9-year old technology platform company located in Nanjing Jiangning Hi-Tech Zone.
San Diego has created a number of "global firsts" in the field of 3D printed drugs. With more than 233 patent applications, accounting for more than 20% in the global 3D printing drug field, San Diegui has become the company with the most complete patent layout and the largest number of applications in the field, and has already obtained 7 IND approvals for 5 products in China and the U.S., which is the first place in the global 3D printing drug field in terms of the number of products.
Previously, the World Economic Forum unveiled the "2024 Technology Pioneers List", and Nanjing Sandiagen Pharmaceutical Technology Co., Ltd. was successfully ranked among the top 100 in the world by virtue of its outstanding innovation and leadership in the field of 3D printed drugs.
The list brought together 100 top companies from 23 countries, among which 11 Chinese companies stood out, and San Diegui, together with two other companies from Jiangsu Province, became the only company from Nanjing on the list.
3D printed drug equipment researched by the company is printing drugs in the laboratory of San Diegui Pharmaceutical Technology Co. The company has built a continuous 3D printing drug production center in line with GMP standards, and the annual capacity of the first continuous production line can reach 75 million tablets.
Dr. Cheng Senping, Founder and CEO of Tricycle, introduced that Tricycle has developed the world's first MED® 3D printing drug research and development equipment, which is capable of freely constructing 3D microstructures of drugs by producing and manufacturing three-dimensional entities through the method of "layer-by-layer printing and layer-by-layer stacking". This 3D microstructure can control the release behavior of the drug, according to the differences in the release and absorption of the drug in different parts of the gastrointestinal tract, the drug will be precisely delivered to the specific site, so that the drug will be released at the right time and location after entering the human body.
Currently, Tridium has several drug development technology platforms to fulfill different therapeutic needs.For example, the 3D microstructured gastric retention platform can help patients change their medication taking time from 3 times a day to once a week, which meets the needs of people who have difficulty in taking medication and people who have inconvenient time to take medication.
